In re Omeprazole Patent Litigation

NOTE: ThiS order is n0nprecedentia1.

United States Court of Appeals for the FederaI Circuit

IN RE OMEPRAZOLE PATENT LITIGATION

ASTRAZENECA AB, AKTIEBOLAGET HASSLE,

KBI-E, INC., KBI, INC., AND ASTRAZENECArLP, Plaintiffs-Appellees,

V.

MYLAN LABORATORIES INC. (N0w KNOWN As

MYLAN INC.), MYLAN PHARMACEUTICALS INC., LABORATORIOS DR. ESTEVE, S.A., AND ESTEVE QUIMICA, S.A.,

Defendan,ts-Appellants.

2010-1414

Appeal from the United States DiStrict C0urt for the S0uthern District of NeW Y0rk in case n0S. 00-CV-6749, 03-CV-6057, M-21-81, and MDL n0. 1291, Judge Barbara S. J0nes.

ON MOTION

ORDER

ASTRAZENECA AB V. MYLAN LABS 2

AstraZeneca AB, et al. move for a 30 day extension of tirne, until N0vember 15, 201U, to file their response brief and for a 4-day extension of time, until Dece1nber 3, 2010, for Mylan Laboratories, Inc., et al. to file their reply brief Up0n consideration thereof

I'r ls ORnERED THAT:

The motion is granted

FoR THE CoURT

UCT 1 5 2010 /s/ J an Horbal3[

Date J an H0rbaly

Clerk _ cc: Errol B. Taylor, Esq.

James H. Wallace, Jr., Esq. lLED

521 “~’ve2zrfe;.rast§:°"

OCT 1 5 2010 .lAN HORBALY

CLERK